Title : A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.

Pub. Date : 2022 Mar 1

PMID : 34648657






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In randomized clinical trials, the androgen receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). enzalutamide androgen receptor Homo sapiens